Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing.

Kleinerman ES, Yu L, Dao J, Hayes-Jordan AA, Lindsey B, Kawedia JD, Stewart J, Gordon N.

Sarcoma. 2018 Jan 21;2018:3143096. doi: 10.1155/2018/3143096. eCollection 2018.

2.

Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients.

Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES.

Mol Cancer Ther. 2018 Mar 28. pii: molcanther.0901.2017. doi: 10.1158/1535-7163.MCT-17-0901. [Epub ahead of print]

PMID:
29592877
3.

Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy.

Santiago-O'Farrill JM, Kleinerman ES, Hollomon MG, Livingston A, Wang WL, Tsai JW, Gordon NB.

Oncotarget. 2017 Aug 17;9(2):1602-1616. doi: 10.18632/oncotarget.20308. eCollection 2018 Jan 5.

4.

miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

Yang Y, Huang G, Zhou Z, Fewell JG, Kleinerman ES.

Mol Cancer Ther. 2018 Jan;17(1):130-139. doi: 10.1158/1535-7163.MCT-17-0042. Epub 2017 Oct 27.

PMID:
29079708
5.

Diet and exercise interventions for pediatric cancer patients during therapy: tipping the scales for better outcomes.

Schadler KL, Kleinerman ES, Chandra J.

Pediatr Res. 2018 Jan;83(1-1):50-56. doi: 10.1038/pr.2017.225. Epub 2017 Oct 25. Review.

PMID:
29068433
6.

Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.

Kiany S, Huang G, Kleinerman ES.

Oncoimmunology. 2017 Jul 11;6(8):e1333214. doi: 10.1080/2162402X.2017.1333214. eCollection 2017.

PMID:
28919994
7.

BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8065-8070. doi: 10.1073/pnas.1704173114. Epub 2017 Jul 11.

8.

Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines.

Aquino-López A, Senyukov VV, Vlasic Z, Kleinerman ES, Lee DA.

Front Immunol. 2017 Apr 6;8:391. doi: 10.3389/fimmu.2017.00391. eCollection 2017.

9.

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases.

Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S.

Cancer Immunol Res. 2017 Apr;5(4):300-311. doi: 10.1158/2326-6066.CIR-16-0234. Epub 2017 Feb 21.

10.

Osteosarcoma Overview.

Lindsey BA, Markel JE, Kleinerman ES.

Rheumatol Ther. 2017 Jun;4(1):25-43. doi: 10.1007/s40744-016-0050-2. Epub 2016 Dec 8. Review.

11.

Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.

Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S.

Clin Cancer Res. 2016 Aug 1;22(15):3876-83. doi: 10.1158/1078-0432.CCR-15-2052. Epub 2016 Mar 15.

12.

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience.

Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V.

Oncoscience. 2014 Jul 27;1(7):522-530.

13.

Osteosarcoma: the state of affairs dictates a change. What do we know?

Kleinerman ES, Mary V, John A.

Adv Exp Med Biol. 2014;804:vii-viii. No abstract available.

PMID:
25207354
14.

Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.

Huang G, Nishimoto K, Yang Y, Kleinerman ES.

Adv Exp Med Biol. 2014;804:203-17. doi: 10.1007/978-3-319-04843-7_11. Review.

PMID:
24924176
15.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.

Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574. Epub 2014 May 6.

16.

Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.

Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES.

Pediatr Blood Cancer. 2014 Aug;61(8):1362-8. doi: 10.1002/pbc.25019. Epub 2014 Mar 9.

17.

CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.

Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S.

Mol Cancer. 2014 Feb 24;13:34. doi: 10.1186/1476-4598-13-34.

18.

Universal marker and detection tool for human sarcoma circulating tumor cells.

Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S.

Cancer Res. 2014 Mar 15;74(6):1645-50. doi: 10.1158/0008-5472.CAN-13-1739. Epub 2014 Jan 21.

19.

EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.

Zhou Z, Yu L, Kleinerman ES.

Cancer. 2014 Feb 15;120(4):579-88. doi: 10.1002/cncr.28555. Epub 2014 Jan 10.

20.

Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.

Hamdan R, Zhou Z, Kleinerman ES.

Mol Cancer Ther. 2014 Feb;13(2):483-91. doi: 10.1158/1535-7163.MCT-13-0447. Epub 2013 Nov 26.

21.

The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.

Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA.

Pharm Res. 2015 Mar;32(3):779-92. doi: 10.1007/s11095-013-1231-0. Epub 2013 Nov 8.

22.

Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells.

Hollomon MG, Gordon N, Santiago-O'Farrill JM, Kleinerman ES.

BMC Cancer. 2013 Oct 26;13:500. doi: 10.1186/1471-2407-13-500.

23.

Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.

Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES.

Pediatr Blood Cancer. 2014 Apr;61(4):618-26. doi: 10.1002/pbc.24801. Epub 2013 Oct 18.

24.
25.

Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Rao-Bindal K, Rao CK, Yu L, Kleinerman ES.

Pediatr Blood Cancer. 2013 Apr;60(4):575-9. doi: 10.1002/pbc.24412. Epub 2012 Dec 19.

26.

Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression.

Koshkina NV, Yang G, Kleinerman ES.

Curr Cancer Drug Targets. 2013 Jan;13(1):48-56.

PMID:
22920438
27.

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.

Rao-Bindal K, Zhou Z, Kleinerman ES.

Cell Death Dis. 2012 Aug 9;3:e369. doi: 10.1038/cddis.2012.101.

28.

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.

Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM.

Oncogenesis. 2012 Nov 19;1:e34. doi: 10.1038/oncsis.2012.34.

29.

miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.

Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES.

Cancer Res. 2012 Feb 15;72(4):908-16. doi: 10.1158/0008-5472.CAN-11-1460. Epub 2011 Dec 20.

30.

Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES.

Cancer Res. 2012 Jan 1;72(1):271-81. doi: 10.1158/0008-5472.CAN-11-2778. Epub 2011 Nov 10.

31.

CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor₁₆₅ in Ewing sarcoma cells.

Huang G, Zhou Z, Wang H, Kleinerman ES.

Cancer. 2012 Apr 15;118(8):2106-16. doi: 10.1002/cncr.26488. Epub 2011 Aug 25.

32.

SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes.

Hamdan R, Zhou Z, Kleinerman ES.

Mol Cancer Res. 2011 Nov;9(11):1462-70. doi: 10.1158/1541-7786.MCR-11-0190. Epub 2011 Sep 12.

33.
34.
35.

Epigenetic regulation of apoptosis and cell cycle in osteosarcoma.

Rao-Bindal K, Kleinerman ES.

Sarcoma. 2011;2011:679457. doi: 10.1155/2011/679457. Epub 2010 Dec 27.

36.

Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.

Zhou Z, Stewart KS, Yu L, Kleinerman ES.

Angiogenesis. 2011 May;14(2):125-33. doi: 10.1007/s10456-010-9196-7. Epub 2010 Dec 24.

37.

Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation.

Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES.

Blood. 2011 Jan 13;117(2):719-26. doi: 10.1182/blood-2010-05-284869. Epub 2010 Oct 13.

38.

Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES.

Clin Cancer Res. 2010 Aug 1;16(15):4024-30. doi: 10.1158/1078-0432.CCR-10-0662. Epub 2010 Jun 24.

39.

Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.

Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A.

Cancer. 2010 Aug 15;116(16):3892-902. doi: 10.1002/cncr.25107.

40.

Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.

Gordon N, Kleinerman ES.

J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):189-96. doi: 10.1089/jamp.2009.0812. Review.

41.

The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.

Gordon N, Kleinerman ES.

Cancer Treat Res. 2009;152:497-508. doi: 10.1007/978-1-4419-0284-9_29. Review.

PMID:
20213411
42.

Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.

Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES.

Cancer Res. 2010 Feb 15;70(4):1334-43. doi: 10.1158/0008-5472.CAN-09-2795. Epub 2010 Feb 2.

43.

Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma.

Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES.

Clin Cancer Res. 2010 Feb 1;16(3):848-56. doi: 10.1158/1078-0432.CCR-09-1299. Epub 2010 Jan 26.

44.

VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL.

Guan H, Zhou Z, Cao Y, Duan X, Kleinerman ES.

Oncol Res. 2009;18(2-3):117-25.

45.
46.

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU 3rd, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA; Children's Oncology Group.

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566.

47.

Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.

Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H.

Int J Cancer. 2009 Dec 1;125(11):2586-94. doi: 10.1002/ijc.24665.

48.

Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors.

Duan X, Guan H, Cao Y, Kleinerman ES.

Cancer. 2009 Jan 1;115(1):13-22. doi: 10.1002/cncr.24013. Review.

49.

COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.

Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF, Kleinerman ES.

J Pediatr Hematol Oncol. 2008 Jul;30(7):507-12. doi: 10.1097/MPH.0b013e31816e238c.

50.

Supplemental Content

Loading ...
Support Center